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IMPORTANCE Whether immune-related adverse events (irAEs) indicate drug activity in

patients treated with immune checkpoint inhibitors remains unknown.
OBJECTIVE To investigate the association between irAEs and recurrence-free survival (RFS) in

the double-blind EORTC 1325/KEYNOTE-054 clinical trial comparing pembrolizumab therapy
and placebo for the treatment of patients with high-risk stage III melanoma.
DESIGN, SETTING, AND PARTICIPANTS A total of 1019 adults with stage III melanoma were
randomly assigned on a 1:1 ratio to receive treatment with pembrolizumab therapy or
placebo. Eligible patients were adults 18 years and older with complete resection of
cutaneous melanoma metastatic to lymph nodes, classified with stage IIIA (at least 1
micrometastasis measuring >1 mm in greatest diameter), IIIB, or IIIC (without in-transit
metastasis) cancer. Patients were randomized from August 26, 2015, to November 14, 2016.
The clinical cutoff for the data set was October 2, 2017. Analyses were then performed on the
database, which was locked on November 28, 2017.
INTERVENTIONS Participants were scheduled to receive 200 mg of pembrolizumab or
placebo every 3 weeks for a total of 18 doses for approximately 1 year or until disease
recurrence, unacceptable toxic effects, major protocol violation, or withdrawal of consent.
MAIN OUTCOMES AND MEASURES The association between irAEs and RFS was estimated using
a Cox model adjusted for sex, age, and AJCC-7 stage, with a time-varying covariate that had a
value of 0 before irAE onset and 1 after irAE onset.
RESULTS Of 1011 patients who began treatment with pembrolizumab therapy or placebo, 622
(61.5%) were men and 389 (38.5%) were women; 386 patients (38.2%) were aged 50 to 64
years, 377 (37.3%) were younger than 50 years, and 248 (24.5%) were 65 years and older.
Consistent with the reported main analysis in the intent-to-treat population, RFS was longer
in the pembrolizumab arm compared with the placebo arm (hazard ratio [HR], 0.56; 98.4%
CI, 0.43-0.74) among patients who started treatment. The incidence of irAEs was 190 (37.4%)
in the pembrolizumab arm (n = 509) and 45 (9.0%) in the placebo arm (n = 502); in each
treatment group, the incidence was similar for men and women. The occurrence of an irAE
was associated with a longer RFS in the pembrolizumab arm (HR, 0.61; 95% CI, 0.39-0.95;
P = .03) in both men and women. However, in the placebo arm, this association was not
significant. Compared with the placebo arm, the reduction in the hazard of recurrence or
death in the pembrolizumab arm was greater after the onset of an irAE than without or
before an irAE (HR, 0.37; 95% CI, 0.24-0.57 vs HR, 0.61; 95% CI, 0.49-0.77, respectively;
P = .03).
CONCLUSIONS AND RELEVANCE In this study, the occurrence of an irAE was associated with a

longer RFS in the pembrolizumab arm.
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I

mmune-related adverse events (irAEs) are commonly observed in patients treated with immunotherapies that include immune checkpoint inhibitors (ICIs), such as anti–
CTLA-4 (anti-cytotoxic T-lymphocyte–associated protein 4) and
anti–PD-L1 (anti–programmed cell death ligand 1).1-4 Adverse
events (AEs) related to autoimmunity have also been recognized in the context of treatments with other agents, such as
interleukin-25,6 and interferon.7-9
An association between irAEs and improved outcomes
of patients treated with ICIs has been reported for both anti–
CTLA-4 and anti–PD-1 (anti–programmed cell death 1),
mostly in the context of melanoma10-13 and lung cancer.14,15
However, it remains uncertain whether these observations
can be explained by the role of irAEs as an indicator of drug
activity. These associations reported in advanced disease
require validation in larger studies with prospectively collected data and a control group of patients who are not
treated with ICIs. Furthermore, adequate statistical methods should be used, as a simple comparison of patients with
and without irAEs is subject to bias and may produce spurious conclusions because patients who die or experience disease progression have a shorter follow-up period and less
treatment exposure than those who do not.8,16 In addition,
little is known regarding the impact of sex on the association between irAEs and outcomes of patients treated with
ICIs; sex is a factor that has been reported to be associated
with outcomes of patients treated with ICIs.17
The EORTC 1325/KEYNOTE-054 (EORTC 1325/KN-054)
clinical trial demonstrated that treatment with adjuvant
pembrolizumab therapy, compared with placebo, prolonged
recurrence-free survival (RFS) in patients with stage III
melanoma.18 In this study, we investigated the association
between irAEs and RFS in the EORTC 1325/KN-054 clinical
trial. We performed separate analyses by treatment and sex
and investigated the influence of systemic steroid use on
the outcome. The trial protocol is available in Supplement 1.

Methods
Patients
Details of the inclusion criteria and study design have been
previously reported.18 In brief, patients 18 years and older
with completely resected histologically confirmed cutaneous melanoma metastatic to regional lymph nodes were
eligible to participate in the EORTC 1325/KN-054 clinical
trial. Patients had either stage IIIA (those with category N1a
or N2a had to have at least 1 micrometastasis measuring
>1 mm in greatest diameter), IIIB, or IIIC (excluding those
with in-transit metastasis) disease according to the 2009
classification in AJCC Cancer Staging Manual, 7th edition
(AJCC-7). 14,19 Complete regional lymphadenectomy was
required within 13 weeks before the start of treatment.
Exclusion criteria included having an Eastern Cooperative
Oncology Group performance-status score of more than 1,
an autoimmune disease, uncontrolled infections, systemic
corticosteroid use, and previous systemic therapy for
melanoma.
520

Key Points
Question Are immune-related adverse events associated with
recurrence-free survival in patients with high-risk stage III
melanoma treated with pembrolizumab therapy compared with
placebo?
Findings In this secondary analysis of a randomized clinical trial of
1019 adults with stage III melanoma, the occurrence of an
immune-related adverse event was associated with longer
recurrence-free survival among both men and women in the
pembrolizumab arm. However, in the placebo arm, this association
was not significant.
Meaning These findings suggest that the occurrence of an
immune-related adverse event is an indicator of pembrolizumab
activity in patients with high-risk stage III melanoma.

Study Design and Randomization
Patients were randomly assigned on a 1:1 ratio to receive either
an intravenous infusion of 200 mg of pembrolizumab therapy
or placebo every 3 weeks for a total of 18 doses (approximately 1 year) or until disease recurrence, unacceptable toxic
effects, major protocol violation, or withdrawal of consent. Registration was conducted centrally at the European Organisation for Research and Treatment of Cancer (EORTC) headquarters. Randomization was stratified by the patient’s cancer stage
(stage IIIA, IIIB, or IIIC with 1-3 positive lymph nodes or stage
IIIC with >3 positive lymph nodes) and geographic region
(17 regions, each comprising 1-3 countries). Only the local pharmacists were aware of trial-group assignments, whereas the
clinical investigators, patients, and individuals collecting or
analyzing the data were not. The study was approved by independent ethics committees of all participating institutions
(eTable 7 in Supplement 2) and conducted in accordance with
the Declaration of Helsinki 20 and the Guideline for Good
Clinical Practice.21 All patients provided written informed
consent.
The primary end point of the clinical trial was RFS. Patients were randomized from August 26, 2015, to November
14, 2016. The clinical cutoff for the data set was October 2, 2017.
Analyses were then performed on the database, which was
locked on November 28, 2017.

Assessment
Computed tomography and/or magnetic resonance imaging
was performed every 12 weeks for the first 2 years, every 6
months through year 5, and annually thereafter. Recurrence
or metastatic lesions had to be histologically confirmed whenever possible. Recurrence-free survival was defined as the time
from randomization until the date of first recurrence (local, regional, or distant metastasis) or death from any cause. For patients without any RFS event (recurrence or death), the
follow-up was censored at the last disease evaluation.
The severity of AEs was graded according to the National
Cancer Institute’s Common Terminology Criteria for Adverse
Events, version 4.0. The irAE terms were predefined in the
study and were AEs that appeared to be associated with the
mechanism of action of pembrolizumab. The following 3
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groups of irAEs were considered: (1) any irAE (endocrine AE,
pneumonitis/interstitial lung disease, sarcoidosis, vitiligo, severe skin reaction, colitis, pancreatitis, hepatitis, nephritis, uveitis, myositis, or myocarditis); (2) endocrine AE (hypothyroidism, hyperthyroidism, thyroiditis, hypophysitis, type 1
diabetes, or adrenal insufficiency); and (3) vitiligo. The irAEs
were reported between the start of treatment and 30 days after the last dose of treatment for all AEs and 90 days after the
last dose of treatment for serious AEs.
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Figure 1. CONSORT Diagram
1464 Patients assessed for eligibility
445 Excluded
342 Did not meet eligibility
criteria
103 Declined to participate

1019 Randomized

Statistical Methods
The standard Cox model, stratified by cancer stage as provided at the time of randomization, was used to compare
placebo to pembrolizumab therapy among patients who
started the treatment.22 Cox models, which included a timevarying covariate that had a value of 0 before the irAE onset
and 1 after the irAE onset, were used to estimate the association between the occurrence of irAEs and RFS (for
patients who did not experience any irAE, this covariate had
a value of 0 during the entire follow-up period). Two models were fitted. Model 1 included the treatment indicator,
the time-varying irAEs indicator, and the interaction term
between these 2 variables. This model was used to estimate
the hazard ratios (HRs) and 95% CIs for RFS associated with
the occurrence of an irAE in the pembrolizumab and placebo arms. The difference in the association of irAEs and
RFS between the 2 arms (ie, the difference between the 2
HRs) was investigated by testing whether the interaction
term in the model was significantly different from 0. Model
2 included only the treatment indicator and the product of
the treatment indicator and the time-varying irAEs indicator, and this model was used to estimate the HR for the randomized treatment in the presence and absence of irAEs. All
models studying the effect of irAEs were adjusted for
AJCC-7 stage provided at randomization (stage IIIA, IIIB, or
IIIC with 1-3 positive lymph nodes and stage IIIC with >3
positive lymph nodes), sex, and age (<50, 50-64, and ≥65
years).
In addition, the influence of steroid use on the study conclusions was investigated by adding the product of the treatment indicator, the time-varying irAE indicator, and the timevarying steroid indicator to the model. Steroid use was modeled
using a time-varying covariate that had a value of 1 after day
30 of systemic steroid use and a value of 0 by day 30 (and for
patients who did not receive any systemic steroids). In the sensitivity analysis, we replaced the 30-day threshold with 14 days.
No evidence of nonproportional hazards was found in any of
the models.
The Aalen-Johansen estimator was used to estimate the
cumulative incidence of an on-study irAE from the start of
treatment.23 The Fine and Gray model was used to investigate the effect of treatment on the incidence of irAEs.23 A model
that included the treatment arm, the covariate of interest, and
the interaction term was used to test the difference in the effect of treatment on the incidence of irAEs between subgroups and to estimate the subdistribution HR within each subgroup. The earliest of the last date of treatment plus 91 days
and the date of death was used as the date of a competing event.
jamaoncology.com

514 Assigned to pembrolizumab arm
509 Started receiving
pembrolizumab treatment
5 Did not receive treatment
3 Withdrew consent
1 Ineligible
1 Other reason

505 Assigned to placebo arm
502 Started receiving
placebo
3 Did not receive placebo
2 Withdrew consent
1 Early progression

19 Remained on pembrolizumab
treatment
208 Discontinued treatment
109 Recurrence
70 Adverse event
18 Patient and investigator
decision
4 Other malignancy
0 Recurrence and other
malignancy
7 Nonadherence/other reason
282 Completed treatment
intervention

6 Remained on placebo
202 Discontinued placebo
179 Recurrence
11 Adverse event
6 Patient and investigator
decision
4 Other malignancy
1 Recurrence and other
malignancy
1 Other reason
294 Completed placebo intervention

509 Included in analysis
5 Excluded (did not start
pembrolizumab treatment)

502 Included in analysis
3 Excluded (did not start
placebo)

All analyses were 2-sided with a significance threshold of
P = .05 and were performed using SAS software, version 9.4
(SAS Institute).

Results
Among 1019 randomized patients, 1011 commenced treatment as allocated by randomization and were included in this
analysis (Figure 1). Of those, 622 patients (61.5%) were men and
389 (38.5%) were women; 386 patients (38.2%) were aged 50
to 64 years, 377 (37.3%) were younger than 50 years, and 248
(24.5%) were 65 years and older. The characteristics of these
1011 patients were well balanced in the 2 treatment groups
(Table 1). The median follow-up was 15 months (interquartile
range, 13-17 months).

Incidence of irAEs
As previously reported,18 among patients who started the randomized treatment, the incidence of grade 1 or higher irAEs
in the pembrolizumab arm (n = 509) was 19.4% (95% CI, 16.1%23.0%) at 3 months and 37.4% (95% CI, 33.2%-41.6%) at 15
months and in the placebo arm (n = 502) was 4.0% (95% CI,
2.5%-6.0%) at 3 months and 9.0% (95% CI, 6.7%-11.7%) at 15
months (Table 2 and Figure 2A). The onset of the first irAE occurred within the first 6 months of treatment for most of the
(Reprinted) JAMA Oncology April 2020 Volume 6, Number 4
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Table 1. Characteristics of Patients Who Started Treatment
Treatment Arm, No. (%)a

in the incidence of irAEs in all of these subgroups of patients
(Figure 2B).
Among patients who experienced an irAE, 33 of 190 in the
pembrolizumab arm and 6 of 45 in the placebo arm discontinued treatment owing to an irAE. Among patients with an endocrine irAE, 9 of 119 in the pembrolizumab arm and 1 of 25 in
the placebo arm discontinued treatment owing to an irAE.
Among patients with vitiligo, only 1 from the pembrolizumab
arm discontinued treatment owing to an irAE (pneumonitis,
not vitiligo). Among patients with grade 3 or higher irAEs, 19
of 36 from the pembrolizumab arm and 3 of 3 from the placebo arm discontinued treatment owing to an irAE.

Pembrolizumab
(n = 509)

Placebo
(n = 502)

Male

320 (62.9)

302 (60.2)

Female

189 (37.1)

200 (39.8)

<50

192 (37.7)

185 (36.9)

50-64

193 (37.9)

193 (38.4)

≥65

124 (24.4)

124 (24.7)

<25

154 (30.3)

182 (36.3)

Treatment, irAEs, and RFS

25-29.9

222 (43.6)

194 (38.6)

≥30

121 (23.8)

123 (24.5)

Unknown

12 (2.4)

3 (0.6)

III A

80 (15.7)

80 (15.9)

III B

233 (45.8)

228 (45.4)

III C (1-3 LN+)

95 (18.7)

92 (18.3)

III C (>3 LN+)

101 (19.8)

102 (20.3)

III A

77 (15.1)

76 (15.1)

III B

236 (46.4)

230 (45.8)

III C (1-3 LN+)

87 (17.1)

94 (18.7)

III C (>3 LN+)

109 (21.4)

102 (20.3)

Microscopic

185 (36.3)

161 (32.1)

Macroscopic

324 (63.7)

341 (67.9)

1

224 (44.0)

236 (47.0)

2-3

176 (34.6)

164 (32.7)

>3

109 (21.4)

102 (20.3)

No

228 (44.8)

250 (49.8)

Yes

207 (40.7)

196 (39.0)

Unknown

74 (14.5)

56 (11.2)

Positive

423 (83.1)

423 (84.3)

Negative

59 (11.6)

57 (11.4)

Indeterminate

27 (5.3)

22 (4.4)

The EORTC 1325/KN-054 study previously reported that treatment with pembrolizumab therapy resulted in a longer RFS in
the intent-to-treat population (HR, 0.57; 98.4% CI, 0.43-0.74).16
Consistent with these results, a prolonged RFS was observed
in the pembrolizumab compared with the placebo arm in patients who started the treatment allocated at randomization
(HR, 0.56; 98.4% CI, 0.43-0.74).
Based on model 1, the occurrence of an irAE was associated with a longer RFS in the pembrolizumab arm (HR, 0.61;
95% CI, 0.39-0.95; P = .03) but not in the placebo arm (HR, 1.37;
95% CI, 0.82-2.29; P = .21). The difference between the 2 HRs
was unlikely due to chance (P = .02). Compared with the placebo arm, the reduction in the hazard of recurrence or death
was greater (P = .03) after the onset of an irAE (HR, 0.37; 95%
CI, 0.24-0.57) than without or before the onset of an irAE (HR,
0.62; 95% CI, 0.49-0.78) in patients who started pembrolizumab treatment (model 2 in Table 3). Similar results were obtained in each sex group. In men, the estimated HR was 0.36
(95% CI, 0.21-0.63) after the onset of an irAE and 0.59 (95%
CI, 0.44-0.79) without or before the onset of an irAE compared with the entire group of patients in the placebo arm. In
women, the 2 HR estimates were 0.42 (95% CI, 0.22-0.82) after the onset of an irAE and 0.71 (95% CI, 0.48-1.04) without
or before the onset of an irAE.
Comparable results were obtained when only endocrine
AEs were considered (Table 3). Patients treated with pembrolizumab therapy appeared to have a particularly low risk of recurrence or death after a vitiligo onset (HR, 0.13; 95% CI, 0.020.95). However, bec ause only 2 4 patients from the
pembrolizumab arm developed vitiligo, large uncertainty existed about this estimate, as reflected by the width of the CI.
The occurrence of a severe irAE among patients treated with
pembrolizumab therapy was not significantly associated with
a prolonged RFS (Table 3).

Characteristic
Sex

Age, y

BMI

AJCC-7 stage at randomization

AJCC-7 stage at baseline

Type of LN involvement at baseline

No. of LNs involved at baseline

Ulceration of primary tumor at baseline

PD-L1

Abbreviations: AJCC-7, AJCC Cancer Staging Manual, 7th edition; BMI, body
mass index (calculated as weight in kilograms divided by height in meters
squared); LN, lymph node; LN+, positive lymph node; PD-L1, programmed cell
death ligand 1.
a

Totals may not equal 100% because of rounding.

patients who experienced an irAE. The most common irAEs
included endocrine disorders (in particular, hypothyroidism
and hyperthyroidism) and vitiligo. In both treatment arms, the
incidence of irAEs was similar for men (36.6% [pembrolizumab arm]) and women (38.6% [pembrolizumab arm]; Table 2
and eTable 1 in Supplement 2), for younger and older patients
(eTable 2 in Supplement 2), and across different disease stages
(eTable 3 in Supplement 2). The exposure to pembrolizumab
therapy compared with placebo resulted in similar increases
522

Treatment, irAEs, Systemic Steroids, and RFS
Systemic steroids were used 30 days or longer from the start
of the randomized treatment until 90 days from the last dose
of treatment in 94 of 509 patients (18.5%) from the pembrolizumab arm and 25 of 502 patients (5.0%) from the placebo arm.
Among patients with an irAE, systemic steroids were used 30
days or longer in 63 of 190 patients (33.2%) from the pembrolizumab arm and 5 of 45 patients (11.1%) from the placebo arm
(eTable 4 in Supplement 2). Common irAEs among the 63 pa-
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Table 2. Immune-Related Adverse Events in Each Treatment Arm by Sex
Treatment Arm, No. (%)

Adverse Event
Any immune-related event

Pembrolizumab
Men
Women
(n = 320)
(n = 189)
117 (36.6)
73 (38.6)

Placebo
Men
(n = 302)
22 (7.3)

Women
(n = 200)
23 (11.5)

Endocrine disorder

70 (21.9)

49 (25.9)

10 (3.3)

15 (7.5)

Hypothyroidism

41 (12.8)

32 (16.9)

4 (1.3)

10 (5.0)

Hyperthyroidism

30 (9.4)

22 (11.6)

2 (0.7)

4 (2.0)

Thyroiditis

11 (3.4)

5 (2.6)

1 (0.3)

0

Hypophysitis (including hypopituitarism)

4 (1.3)

7 (3.7)

1 (0.3)

0

Type 1 diabetes

3 (0.9)

2 (1.1)

0

0

Adrenal insufficiency

4 (1.3)

1 (0.5)

2 (0.7)

2 (1.0)

17 (5.3)

7 (3.7)

2 (0.7)

1 (0.5)

Pneumonitis or interstitial lung disease

12 (3.8)

5 (2.6)

2 (0.7)

1 (0.5)

Sarcoidosis

0

Respiratory/thoracic disorder

5 (1.6)

2 (1.1)

0

Skin disorder

20 (6.3)

7 (3.7)

3 (1.0)

5 (2.5)

Vitiligo

18 (5.6)

6 (3.2)

3 (1.0)

5 (2.5)

Severe skin reaction

2 (0.6)

1 (0.5)

0

0

Gastrointestinal disorder

11 (3.4)

9 (4.8)

4 (1.3)

0

10 (3.1)

9 (4.8)

3 (1.0)

0

Colitis
Pancreatitis
Hepatobiliary disorder

2 (0.6)

0 (0.0)

1 (0.3)

0

4 (1.3)

5 (2.6)

1 (0.3)

0

Hepatitis

4 (1.3)

5 (2.6)

1 (0.3)

0

Other disorder

9 (2.8)

6 (3.2)

3 (1.0)

2 (1.0)

Nephritis

1 (0.3)

1 (0.5)

0

1 (0.5)

Uveitis

1 (0.3)

1 (0.5)

0

0

Myositis

0

1 (0.5)

1 (0.3)

0

Myocarditis

1 (0.3)

0

0

0

tients in the pembrolizumab arm, for which systemic steroids were used, included 18 incidents (28.6%) of colitis, 13
(20.6%) of pneumonitis, 9 (14.3%) of hypophysitis, 4 (6.3%)
of hepatitis, and 4 (6.3%) of hyperthyroidism. In the placebo
arm, 2 patients received systemic steroids to treat pneumonitis, 1 to treat hepatitis, 1 to treat colitis, and 1 to treat adrenal
insufficiency. Among those with grade 3 or higher irAEs, 26
of 36 patients from the pembrolizumab arm received systemic steroids for 30 days or longer. Compared with the placebo arm, the estimated HR was 0.50 (95% CI, 0.23-1.07) after an irAE onset and after day 30 of systemic steroid use and
0.34 (95% CI, 0.21-0.56) after an irAE onset and without systemic steroid use or by day 30 of steroid use (modified model
2 in eTable 5 in Supplement 2). In the sensitivity analysis, in
which the 30-day threshold was replaced by 14 days, the 2 estimates were closer to each other (eTable 6 in Supplement 2).

Discussion
We evaluated the association between irAEs and patient outcomes in a double-blind randomized clinical trial comparing
treatment with pembrolizumab therapy and placebo in patients with high-risk stage III melanoma. Compared with the
placebo arm, the reduction in the hazard of recurrence or death
in the pembrolizumab arm was substantially higher after the
onset of an irAE (HR, 0.37; 95% CI, 0.24-0.57) than without
jamaoncology.com

or before the onset of an irAE (HR, 0.61; 95% CI, 0.49-0.77).
A similar pattern was observed for men and women. In the placebo arm, no association between irAEs and RFS was found.
Knowledge about the indicators of ICI activity in patients
with adjuvant melanoma is of substantial importance. Treatment with ICIs has been previously associated with improved outcomes for patients with advanced melanoma,24 has
indicated efficacy in the adjuvant setting, and is becoming the
standard of care among patients with high-risk stage III
melanoma. In the EORTC 18071 study, which had a median
follow-up period of 5.3 years, treatment with adjuvant ipilimumab therapy was associated with prolonged RFS (HR, 0.76;
95% CI, 0.64-0.89) and overall survival (HR, 0.72; 95% CI, 0.580.88) compared with placebo.25 The EORTC 1325/KN-054 study
reported an improvement in RFS (HR, 0.57; 98.4% CI, 0.430.74) among patients randomized to be treated with pembrolizumab therapy compared with placebo.18 The Checkmate 238
study reported an improvement in RFS (HR, 0.65; 97.56% CI,
0.51-0.83) in patients treated with nivolumab therapy compared with ipilimumab therapy.26
Our observation of an association between irAEs and better outcomes among patients treated with ICIs is in line with
previous studies of patients with advanced melanoma10-13 and
lung cancer.14,15 An association between autoimmunity and patient outcomes has also been reported for other immunotherapies, including interleukin-2, 6 interferon, 7,27 and intralesional talimogene laherparepvec injection.28 Unfortunately,
(Reprinted) JAMA Oncology April 2020 Volume 6, Number 4
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Figure 2. Incidence of Immune-Related Adverse Events by Treatment Arm
Among All Patients and Subgroups of Patients
A Cumulative incidence of irAEs by treatment arm in all patients

Cumulative Incidence of Any irAE, %

50
Pembrolizumab

40

30

20
Placebo
10

0
0

3

6

9

12

15

No. of Months
No. at risk
Pembrolizumab
Placebo

B

509
502

410
481
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Hazard ratios of irAE incidence by subgroups
Pembrolizumab
Arm

Placebo Arm

Events, Patients,
No.
No.

Events, Patients,
No.
No.

HR
(95% or 99% CI)a

Male

117

320

22

302

5.96 (3.27-10.84)

Female

73

189

23

200

4.01 (2.17-7.40)

<50

76

192

17

185

5.33 (2.67-10.64)

50-64

72

193

15

193

5.71 (2.74-11.88)

≥65

42

124

13

124

3.62 (1.61-8.13)

9

80

3.42 (1.27-9.18)

Source

Increased
Incidence for
Placebo

Increased
Incidence for
Pembrolizumab

Sex

.23

Age, y

.52

Cancer stage at randomization

.72

III A

27

80

III B

87

233

18

228

5.63 (2.90-10.94)

III C (1-3 LN+)

35

95

9

92

4.53 (1.71-11.97)

III C (>3 LN+)

41

101

9

102

5.57 (2.16-14.35)

190

509

45

502

4.95 (3.58-6.85)

Total

P for
Interaction

A, In the pembrolizumab arm
(n = 509), 190 irAEs occurred, with a
percentage incidence of 19.4% (95%
CI, 16.1%-23.0%) at 3 months and
37.4% (95% CI, 33.2%-41.6%) at 15
months. In the placebo arm
(n = 502), 45 irAEs occurred, with a
percentage incidence of 4.0%
(95% CI, 2.5%-6.0%) at 3 months
and 9.0% (95% CI, 6.7%-11.7%) at 15
months. Vertical lines correspond to
the time of censoring. B, The
estimate of the subdistribution
hazard ratio in the whole sample is
based on an unstratified model with
treatment as the only covariate. Blue
boxes are centered on the estimated
subdistribution hazard ratios. The
green diamond is centered on the
overall subdistribution hazard ratio
(dashed line) and covers its 95% CI.
HR indicates hazard ratio; irAE,
immune-related adverse event; and
LN+, positive lymph node.
a

For the whole sample estimate, a
95% CI is shown. For subgroups,
99% CIs are presented.

b

P < .001 corresponds only to the
overall comparison, performed on
all patients: HR, 4.95 (99% CI,
3.58-6.85).

Unadjusted treatment effect, P <.001b
0.1

1

HR of irAE Incidence
(95% CI or 99% CI)a

many of these studies analyzed the data by comparing patients with and without irAEs using a log-rank test or a standard Cox model, which introduces a bias owing to the different follow-up times and treatment exposures between patients
who did and did not develop irAEs. As previously reported, the
size of that bias may be large enough to dramatically change
the study conclusion.8,9,29 In this analysis, we dealt with this
problem by using a time-dependent Cox model. Landmark
analysis comparing the RFS after a landmark point in time from
randomization (eg, 3 or 6 months) between patients with and
without irAEs before that time would be a possible alternative approach. We did not use this method, as it excludes patients with an RFS event before the landmark time and misclassifies those who experience an irAE after the landmark
time, leading to a substantially lower statistical power compared with the method using the time-dependent Cox model.
524
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A recent meta-analysis of patients with advanced or metastatic melanoma reported a higher ICI efficacy regarding overall survival for men (HR, 0.66; 95% CI, 0.55-0.79) compared
with women (HR, 0.79; 95% CI, 0.70-0.90).17 In our adjuvant
study, the treatment HR regarding RFS was 0.53 (99% CI, 0.370.76) for men and 0.62 (99% CI, 0.39-1.00) for women.18 It has
been suggested that the toxic effects profile for ICI may also
be different for men than women.30 In our study, the incidence of irAEs was similar for men (36.6%) and women (38.6%)
in the pembrolizumab arm.
Patients with a history of pneumonitis or autoimmune disease in the past 2 years that required systemic treatment with
steroids were not eligible to participate in our study. Because
steroids are known to be immune-suppressive, treatment with
pembrolizumab therapy was expected to be less effective in
those patients. Consistent with that expectation, the esti-
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mated treatment effect compared with placebo after an irAE
onset and after day 30 of systemic steroid use (HR, 0.50; 95%
CI, 0.23-1.07) appeared to be lower than the treatment effect
after an irAE onset and without steroid use or by day 30 of systemic steroid use (HR, 0.34; 95% CI, 0.21-0.56). Previous studies reported an association between steroid use at the start of
treatment with anti–PD-1 therapies because of disease conditions, such as brain metastasis and pulmonary disease, and
poorer outcomes in lung cancer patients.31,32

Original Investigation Research

Table 3. Treatment Effect in the Presence and Absence
of Immune-Related Adverse Events
Immune-Related Adverse Event Status
and Treatment Arm

Recurrence-Free
Survival,
HR (95% CI)a

P Valuea,b

Any irAE
Placebo

1

Pembrolizumab without/before irAE

0.62 (0.49-0.78)

Pembrolizumab after irAE onset

0.37 (0.24-0.57)

.03

Endocrine irAE

Strengths and Limitations

Placebo

1

Our study has a number of strengths. First, the data were prospectively collected in the framework of a clinical trial with highquality standards regarding assessment of disease and evaluation
of AEs. Second, the study had a large sample that allowed a precise estimation of the association between irAEs and patient outcomes as well as subgroup analyses by sex. Third, we used adequate statistical methods to avoid bias that may have resulted
from the differences in the duration of follow-up and the treatment exposure between patients who did and did not develop
irAEs, and we adjusted the analyses for possible confounders,
including cancer stage, age, and sex.
We were unable to explore the importance of some types
of irAEs (eg, severe skin reactions) owing to the insufficient
number of patients who experienced them. For the same reason, we could not investigate the effects of the characteristics (eg, type, dose, and duration of administration) of the systemic steroid treatments on the outcome.

Pembrolizumab without/before irAE

0.60 (0.48-0.75)

Pembrolizumab after irAE onset

0.34 (0.20-0.57)

Conclusions
Our study observed a strong association between irAEs and
outcomes of patients with high-risk stage III melanoma who
were treated with ICIs, which adds to the growing amount
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